Autophagy is a fundamental cellular recycling process vulnerable to compromise in neurodegeneration. We now report that a cell-penetrating neurotrophic and neuroprotective derivative of the central nervous system (CNS) metabolite, lanthionine ketimine (LK), stimulates autophagy in RG2 glioma and SH-SY5Y neuroblastoma cells at concentrations within or below pharmacological levels reported in previous mouse studies. Autophagy stimulation was evidenced by increased lipidation of microtubule-associated protein 1 light chain 3 (LC3) both in the absence and presence of bafilomycin-A1 which discriminates between effects on autophagic flux versus blockage of autophagy clearance. LKE treatment caused changes in protein level or phosphorylation state of multiple autophagy pathway proteins including mTOR; p70S6 kinase; unc-51-like-kinase-1 (ULK1); beclin-1 and LC3 in a manner essentially identical to effects observed after rapamycin treatment. The LKE site of action was near mTOR because neither LKE nor the mTOR inhibitor rapamycin affected tuberous sclerosis complex (TSC) phosphorylation status upstream from mTOR. Confocal immunofluorescence imaging revealed that LKE specifically decreased mTOR (but not TSC2) colocalization with LAMP2 + lysosomes in RG2 cells, a necessary event for mTORC1-mediated autophagy suppression, whereas rapamycin had no effect. Suppression of the LK-binding adaptor protein CRMP2 (collapsin response mediator protein-2) by means of shRNA resulted in diminished autophagy flux, suggesting that the LKE action on mTOR localization may occur through a novel mechanism involving CRMP2-mediated intracellular trafficking. These findings clarify the mechanism-of-action for LKE in preclinical models of CNS disease, while suggesting possible roles for natural lanthionine metabolites in regulating CNS autophagy.
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Introduction
Autophagy is a normal catabolic process whereby cells recycle damaged proteins, lipid deposits and entire organelles. Macro-autophagy (hereby referred to simply as autophagy) is a common sub-type of autophagy involving the regulated creation, trafficking and fusion of autophagic vesicles (AVs) with lysosomes to form autophagolysosomes (APLs) where the recycling occurs (Dall'Armi et al., 2013; Gallagher and Chan, 2013; Klionsky et al., 2012; Ravikumar et al., 2010; Wirth et al., 2008) . Autophagy is a complex process involving many different protein components, but predominant amongst its regulatory elements are the mammalian target of rapamycin complex-1 (mTORC1) and unc-51-like kinase-1 (ULK1) (Ravikumar et al., 2010; Wirth et al., 2008; Gallagher and Chan, 2013) . mTORC1 is itself a kinase that inhibits
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Abbreviations: AD, Alzheimer's disease; AKT, AKT phosphotidylinositol-3-kinase (protein kinase B); AMPK, AMP-activated protein kinase; APLs, autophagolysosomes; Atg, autophagy protein; AVs, autophagic vesicles; CNS, central nervous system; CRMP2, collapsin-response mediator protein 2; DPYSL2, dihydropyrimidinase-like protein-2; LanCL1, lanthionine cyclase-like protein-1; LC3, microtubule-associated protein 1A/1B-light chain 3 (LC3); LK, lanthionine ketimine; LKE, lanthionine ketimine-ethyl ester; mTOR, mammalian target of rapamycin; mTORC1(2), mTOR complex-1(2); p70S6K, p70S6 ribosomal protein-directed protein kinase; TSC, tuberous sclerosis complex; Tsc1, tuberous sclerosis complex gene-1 (hamartin); Tsc2, tuberous sclerosis complex gene-2 (tuberin); ULK1, uncoordinated 51-like autophagy-regulating kinase.
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